Dr. Adam Boxer has focused his career on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. He is the Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. He is the principal investigator of the Advancing Research and Treatment for FTLD (ARTFL) Rare Disease Clinical Research Consortium, a collaborative project funded by the National Institutes of Health to create a North American research network to support the development of new therapies for FTLD. He also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a multicenter, longitudinal tau PET and biomarker study focused on Progressive Supranuclear Palsy (PSP) and corticobasal degeneration (CBD). Dr. Boxer co-chairs the FTLD Treatment Study Group (FTSG) and the PSP Research Roundtable, both academic-industry collaborative groups focused on therapeutic development.
You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.
